Logo


Better science to diagnose and treat cancer

Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties.


diagnostic

CTT1057
PET Imagine Agent for
Prostate Cancer


therapeutic

CTT1403
Radiotherapeutic for
Prostate Cancer 

Latest News

November 6, 2018

Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer

October 23, 2018

Cancer Targeted Technology Receives an SBIR Grant and Announces Expansion of Its Pipeline

February 12, 2018

Advanced Accelerator Applications Signs Exclusive License Agreement with Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer

View All

  • About Us
    • Management
    • Scientific Advisors and Collaborators
  • Technology
    • Relevant Publications
  • Pipeline
    • CTT1057
    • CTT1403
  • Newsroom
    • Press Releases
    • Events and Presentations
  • Careers
  • Contact Us
  • Home
  • About Us
    • Management
    • Scientific Advisors and Collaborators
  • Technology
    • Relevant Publications
  • Pipeline
    • CTT1057
    • CTT1403
  • Newsroom
    • Press Releases
    • Events and Presentations
  • Careers
  • Contact Us
© 2018  Cancer Targeted TechnologyAll rights reservedWebsite Design: Hane Chow, Inc.